載入中
Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.
收盤時
US$2.84
−US$0.06 · -2.07%
盤後
US$2.93
+US$0.09 · +3.17%
10月12日 下午6:39 ET
盤中時間採用ET。市場資料可能有所延遲。
Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.
日內區間
目前US$2.84
52週區間
目前US$2.84
盤中時間採用ET。市場資料可能有所延遲。
Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.
日內區間
目前US$2.84
52週區間
目前US$2.84
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | 21萬 USD | — | 51.2萬 USD |
| 銷貨成本 | 3.6萬 USD | — | 16.1萬 USD | — | 38.5萬 USD |
| 毛利 | −3.6萬 USD | — | 4.9萬 USD | — | 12.7萬 USD |
| 研究與開發 | 507.1萬 USD | 639.6萬 USD | 476.9萬 USD | 670.3萬 USD | 618.97萬 USD |
| 銷售、一般及管理費用 | 663萬 USD | 743.5萬 USD | 629.1萬 USD | 717.2萬 USD | 707.35萬 USD |
| 營業費用 | 1166.5萬 USD | 1383.1萬 USD | 1106萬 USD | 1387.5萬 USD | 1326.32萬 USD |
| 利息收入 | 67.3萬 USD | 113.3萬 USD | 108.1萬 USD | 10.4萬 USD | 2322 USD |
| 利息支出 | — | — | — | 10.4萬 USD | 322 USD |
| 折舊和攤銷 | 3.6萬 USD | 3.7萬 USD | 4.6萬 USD | 4.2萬 USD | 5.99萬 USD |
| 營業利益 | −1170.1萬 USD | −1383.1萬 USD | −1101.1萬 USD | −1387.5萬 USD | −1313.57萬 USD |
| 淨利 | −1092.7萬 USD | −1255.4萬 USD | −981.1萬 USD | −1359.5萬 USD | −1294.66萬 USD |
公司資料更新於 2026年10月12日。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$6.00
上漲空間 111.27%報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
